



Express Mail No.: EV473970877US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dingivan et al. Confirmation No.: 3565
Serial No.: 10/657,006 Art Unit: 1644
Filed: September 5, 2003 Examiner: Skelding, Zachary S.
For: METHODS OF PREVENTING OR Attorney Docket No.: 10271-116-999
TREATING T CELL
MALIGNANCIES BY
ADMINISTERING ANTI-CD2
ANTIBODIES (as amended)

AMENDMENT UNDER 37 C.F.R. § 1.111

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed October 24, 2006, and in accordance with Rule 111 of the Rules of Practice, Applicants respectfully request that the Examiner consider and enter into the record of the present application the remarks and amendments below.

Applicants submit herewith: (1) a Petition for Extension of Time with a provision authorizing payment of the required fee; (2) an Amendment Fee Transmittal with a provision authorizing payment of the required fee; (3) a Supplemental Information Disclosure Statement with a provision authorizing payment of the required fee; and (4) a revised PTO-1449 Form along with copies of references A151 to A153, B71, and C228-C236 listed on the revised PTO-1449 Form.

It is believed that no additional fees are due in connection with the filing of this Amendment. However, in the event that an additional fee is required, the Commissioner is hereby authorized to charge the required fee(s) to Jones Day Deposit Account No. 50-3013.

Amendments to the Specification begin on page 2.

Amendments to the Claims, as reflected in the listing of the claims, begin on page 3.

Remarks begin on page 7.

03/29/2007 TBESHAWI 00000003 503013 10657006
01 FC:1202 350.00 DA